Spatial transcriptomics unravels novel signaling patterns at the leading edge of oral squamous cell carcinoma.

Authors

null

Rohit Arora

Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada

Rohit Arora , Christian Cao , Mehul Kumar , Ayan Chanda , Divya Samuel , Wayne Matthews , Shamir Chandarana , Robert Hart , Joseph C. Dort , Martin Hyrcza , Pinaki Bose

Organizations

Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada, Department of Surgery, University of Calgary, Calgary, AB, Canada, Ohlson Research Initiative, University of Calgary, Calgary, AB, Canada, Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada

Research Funding

Other

Background: Head and neck cancer is the 6th most common cancer worldwide. Oral squamous cell carcinoma (OSCC) is the most prevalent head and neck cancer that is characterized by aggressive local invasion and metastasis. Despite the leading edge (invasive front) of the tumor being a driver of OSCC pathophysiology, its biology and clinical relevance have not been fully characterized. We used spatial transcriptomics to explore signaling patterns within the leading edge and tumor core. Methods: Fresh-frozen, surgically resected OSCC samples from three HPV-negative OSCC patients were profiled using the 10x Genomics Visium Spatial Gene Expression platform. Leading edge and tumor core regions were defined by pathologist annotations and expression of previously identified edge and core gene signatures from the literature. Spatial differential gene expression (DGE) analysis and pathway analysis was performed using the Seurat package and Ingenuity Pathway Analysis (IPA), respectively. Cell-cell interaction networks were reconstructed using the CellChat package. Results: The leading edge and tumor core displayed unique transcriptional and signaling profiles that were conserved across all three OSCC patient samples. DEG analysis revealed 31 genes enriched in the leading edge and 62 genes enriched in the tumor core with a log2FC > 0.58 and adjusted p-value < 0.01. The top genes upregulated in the leading edge were FN1, COL1A1, COL1A2, IFITM3, and SPARC. Top tumor-core genes included CRCT1, LCE3D, DEFB4A, SPRR2A, and CNFN. IPA analysis of upregulated DEGs in the leading edge and tumor core predicted the activation of wound healing and GP6 signaling pathways, and activation of intrinsic prothrombin activation and MSP-RON signaling pathways, respectively. Cell communication analysis revealed that the leading edge had higher intercellular signaling than the tumor core. Upregulated leading edge cell signaling modules included collagen, CD99, CSPG4, and non-canonical WNT pathways, which have been linked to tumor invasion, metastasis, and adhesion. COL1A1 and COL1A2 ligands and CD44 and SDC1 receptors were upregulated in leading edge signaling. The tumor core was enriched for ANGPTL and PERIOSTIN cell signaling modules. Conclusions: This is the first study to characterize the tumor core and leading edge of OSCC tumors using spatial transcriptomics. Further investigation of the therapeutic potential of identified signaling pathways may improve OSCC outcomes.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Biologic Correlates

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr e18043)

DOI

10.1200/JCO.2022.40.16_suppl.e18043

Abstract #

e18043

Abstract Disclosures

Similar Abstracts

First Author: Sabin Goktas Aydin

Abstract

2024 ASCO Genitourinary Cancers Symposium

Differences in genomic, transcriptomic, and immune landscape of prostate cancer (PCa) based on site of metastasis (mets).

First Author: Umang Swami

Abstract

2022 ASCO Annual Meeting

Apatinib in recurrent or metastatic head and neck cancer patients.

First Author: Qiuji WU